{"prompt": "['3.3.4', 'Rationale for Randomized Cross-over Design', 'The primary objective of this study is to assess patient reported preference for pertuzumab', 'and trastuzumab FDC SC. Patients will be randomized to receive either pertuzumab and', 'trastuzumab FDC SC for three treatment cycles followed by P+H IV for three treatment', 'cycles versus receiving P+H IV first, followed by pertuzumab and trastuzumab FDC SC.', 'Patients in both treatment groups will then choose either IV or SC administered IMPs for', 'their remaining HER2-targeted treatment cycles.', 'Randomization accommodates potential treatment sequencing-related differences such as in', 'the nature and/or frequency of administration-related reactions (ARRs) with either', 'administration route (e.g. if ARRs to IV formulation occur more frequently following the', 'treatment break for surgery and/or with a loading dose) or in AEs attributable to switching', 'administration routes. At the same time, the cross-over design provides exposure to both', 'study regimens allowing each patient to act as their own control for patient reported', 'outcomes (PROs) measured after study Cycle 3 and study Cycle 6.', '3.3.5', 'Rationale for Patient Reported Outcome Assessments', 'Early breast cancer is often asymptomatic, especially after tumour removal, thus it is', 'important to assess treatment impact and tolerability to inform the benefit-risk ratio for a', 'patient on adjuvant therapy. The PPQ used to assess the primary study endpoint has been', 'developed in clinical trials assessing patient preference for SC administered monoclonal', 'antibodies. An interview-based assessment was first developed to assess patient preference', 'for Herceptin SC in a clinical trial of adjuvant Herceptin SC and IV in HER2+ EBC [Study', 'MO22982, Pivot et al. 2013]. Interview questions were based on input from experienced', 'clinicians, chemotherapy nurses and psychologists and were tested with patient volunteers', 'prior to use in the study. The three interview questions identified as most informative in the', 'Herceptin MO22982 study were then administered as the patient-completed PPQ in a', 'subsequent lymphoma study evaluating preference for SC or IV administered rituximab', '[PrefMab study, Rummel et al. 2017]. Notably, PPQ endpoints collected in this study were', 'considered adequate evidence for preference claims included in rituximab SC product', 'labelling [Rituxan HycelaTM Package Insert 2017]. The TASQ questionnaires used in this', 'study have been adapted from administration satisfaction questionnaires used in the', 'aforementioned PrefMab study.', \"Health-related quality of life evaluations in this study will contextualize a patient's experience\", 'on trial, elucidating symptom and treatment burden between P+H IV and pertuzumab and', 'trastuzumab FDC SC. Because treatment-related side effects have the potential to affect', 'patient functioning and HRQoL, it is crucial to characterize not only the incidence of these', \"side effects but also the associated trends and burden from the patient's perspective, which\", 'would contribute to a more comprehensive understanding of treatment impact and tolerability.', 'The EORTC QLQ-C30, is a well-known and commonly used questionnaire with strong', 'demonstrated psychometric properties of both reliability and validity.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '41 / Protocol MO40628, Version 12']['4.', 'MATERIALS AND METHODS', '4.1', 'PATIENTS', 'Adult patients with HER2+ EBC who have received neoadjuvant Perjeta and Herceptin, and', 'have completed neoadjuvant chemotherapy and subsequently undergone surgery for their', 'breast cancer will be enrolled in the study.', '4.1.1', 'Inclusion Criteria', 'Patients must meet the following criteria for study entry:', 'Disease-specific criteria', 'Female or male with histologically confirmed, HER2+ inflammatory, locally advanced or', 'early-stage breast cancer who have received neoadjuvant Perjeta + Herceptin and have', 'completed neoadjuvant chemotherapy and subsequently undergone surgery for their', 'breast cancer.', 'Note: The neoadjuvant chemotherapy regimen (including type and sequencing of', 'selected agents) and the number of neoadjuvant Perjeta and Herceptin treatment cycles', 'are at the discretion of the treating physician and patient. Subcutaneously administered', 'Herceptin may have been used in the neoadjuvant setting. The use of any trastuzumab', 'biosimilars in the neoadjuvant setting is not allowed.', 'HER2+ breast cancer assessed at the local laboratory prior to initiation of neoadjuvant', 'therapy. HER2+ status must be determined based on breast biopsy material obtained', 'prior to neoadjuvant treatment and is defined as 3+ by immunohistochemistry (IHC)', 'and/or positive by HER2 amplification by in situ hybridization (ISH) with a ratio of 2 for', 'the number of HER2 gene copies to the number of chromosome 17 copies', 'Hormone receptor status of the primary tumour determined by local assessment.', 'Hormone receptor-positive status may be either positive (i.e. ER-positive and/or PgR-', 'positive) or negative (i.e. ER-negative and PgR-negative)', 'Completed all neoadjuvant chemotherapy and surgery. Adjuvant radiotherapy may be', 'planned or ongoing at study entry and adjuvant hormone therapy is allowed during the', 'study. Note that study treatment cannot be initiated within < 2 weeks of surgery but must', 'be initiated 9 weeks from the last administration of systemic neoadjuvant therapy.', 'No evidence of residual, locally recurrent or metastatic disease after completion of', 'surgery. Patients with clinical suspicion of metastases must undergo radiological', 'assessments per institutional practice to rule out distant disease.', \"Wound healing after breast cancer surgery adequate per investigator's assessment to\", 'allow initiation of study treatment within 9 weeks of last systemic neoadjuvant therapy', 'No adjuvant chemotherapy planned. Note that adjuvant hormonal treatment is allowed', 'during the study.', 'General criteria', 'Signed Informed Consent Form', 'Age 18 years at time of signing Informed Consent Form', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '42 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}